Anti-Infectious Agents against MRSA

Clinically useful antibiotics, β-lactams and vancomycin, are known to inhibit bacterial cell wall peptidoglycan synthesis. Methicillin-resistant Staphylococcus aureus (MRSA) has a unique cell wall structure consisting of peptidoglycan and wall teichoic acid. In recent years, new anti-infectious agen...

Descripción completa

Detalles Bibliográficos
Autores principales: Koyama, Nobuhiro, Inokoshi, Junji, Tomoda, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269750/
https://www.ncbi.nlm.nih.gov/pubmed/23262449
http://dx.doi.org/10.3390/molecules18010204
_version_ 1783376540206104576
author Koyama, Nobuhiro
Inokoshi, Junji
Tomoda, Hiroshi
author_facet Koyama, Nobuhiro
Inokoshi, Junji
Tomoda, Hiroshi
author_sort Koyama, Nobuhiro
collection PubMed
description Clinically useful antibiotics, β-lactams and vancomycin, are known to inhibit bacterial cell wall peptidoglycan synthesis. Methicillin-resistant Staphylococcus aureus (MRSA) has a unique cell wall structure consisting of peptidoglycan and wall teichoic acid. In recent years, new anti-infectious agents (spirohexaline, tripropeptin C, DMPI, CDFI, cyslabdan, 1835F03, and BPH-652) targeting MRSA cell wall biosynthesis have been discovered using unique screening methods. These agents were found to inhibit important enzymes involved in cell wall biosynthesis such as undecaprenyl pyrophosphate (UPP) synthase, FemA, flippase, or UPP phosphatase. In this review, the discovery, the mechanism of action, and the future of these anti-infectious agents are described.
format Online
Article
Text
id pubmed-6269750
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62697502018-12-14 Anti-Infectious Agents against MRSA Koyama, Nobuhiro Inokoshi, Junji Tomoda, Hiroshi Molecules Review Clinically useful antibiotics, β-lactams and vancomycin, are known to inhibit bacterial cell wall peptidoglycan synthesis. Methicillin-resistant Staphylococcus aureus (MRSA) has a unique cell wall structure consisting of peptidoglycan and wall teichoic acid. In recent years, new anti-infectious agents (spirohexaline, tripropeptin C, DMPI, CDFI, cyslabdan, 1835F03, and BPH-652) targeting MRSA cell wall biosynthesis have been discovered using unique screening methods. These agents were found to inhibit important enzymes involved in cell wall biosynthesis such as undecaprenyl pyrophosphate (UPP) synthase, FemA, flippase, or UPP phosphatase. In this review, the discovery, the mechanism of action, and the future of these anti-infectious agents are described. MDPI 2012-12-24 /pmc/articles/PMC6269750/ /pubmed/23262449 http://dx.doi.org/10.3390/molecules18010204 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Koyama, Nobuhiro
Inokoshi, Junji
Tomoda, Hiroshi
Anti-Infectious Agents against MRSA
title Anti-Infectious Agents against MRSA
title_full Anti-Infectious Agents against MRSA
title_fullStr Anti-Infectious Agents against MRSA
title_full_unstemmed Anti-Infectious Agents against MRSA
title_short Anti-Infectious Agents against MRSA
title_sort anti-infectious agents against mrsa
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269750/
https://www.ncbi.nlm.nih.gov/pubmed/23262449
http://dx.doi.org/10.3390/molecules18010204
work_keys_str_mv AT koyamanobuhiro antiinfectiousagentsagainstmrsa
AT inokoshijunji antiinfectiousagentsagainstmrsa
AT tomodahiroshi antiinfectiousagentsagainstmrsa

Ejemplares similares